(SeaPRwire) – Darmstadt, Germany, April 01, 2026 —
- Expands its downstream purification portfolio with cutting-edge Protein A chromatography technology tailored for scalable production
- Integrates downstream workflows to boost efficiency and enable faster access to critical medical treatments
Merck, a leading science and technology firm, today announced the successful completion of its acquisition of JSR Life Sciences’ chromatography business.
The deal adds Amsphere™ Protein A resins and advanced Protein A chromatography capabilities to Merck’s downstream processing portfolio, supporting efficient, scalable purification of monoclonal antibodies. When combined with Merck’s existing downstream offerings, these new assets help clients enhance productivity and ensure reliable manufacturing from development to commercial scale.
“This acquisition expands our downstream purification capabilities at a time when customers are working to scale biologic production more quickly and efficiently,” said Sebastián Arana, Head of Process Solutions for Merck’s Life Science business. “With our expanded Protein A lineup, we can help clients strengthen process consistency, support reliable large-scale manufacturing, and ultimately accelerate access to life-saving therapies.”
Through the acquisition, Merck gains a Belgium-based chromatography team of over 50 employees that supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide. This team brings strong technical support and application expertise, which will further enhance Merck’s downstream offerings for antibody purification. The chromatography business will be integrated into Merck’s Process Solutions portfolio, which supports clients across biopharmaceutical manufacturing from process development to full-scale production.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare, and electronics sectors. More than 62,000 employees work daily to make a positive impact on millions of lives by creating more joyful and sustainable ways to live. From providing products and services that speed up drug development and manufacturing, to discovering innovative treatments for complex diseases, to enabling smart device technology—Merck has a global presence. In 2025, Merck generated €21.1 billion in sales across 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advancements. This approach has allowed Merck to thrive since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds global rights to the Merck name and brand, with exceptions in the United States and Canada, where its business units operate as MilliporeSigma (life science), EMD Serono (healthcare), and EMD Electronics (electronics).
All Merck press releases are distributed via email at the same time they are posted on the Merck website. To register online, adjust your preferences, or unsubscribe from this service, please visit www.merckgroup.com/subscribe.
Attachment
- Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business
CONTACT: Jenny Wuestner Merck +4915114543158 jenny.wuestner@merckgroup.com
This article is provided by a third-party content provider. SeaPRwire (https://www.seaprwire.com/) makes no warranties or representations regarding its content.
Category: Top News, Daily News
SeaPRwire provides global press release distribution services for companies and organizations, covering more than 6,500 media outlets, 86,000 editors and journalists, and over 3.5 million end-user desktop and mobile apps. SeaPRwire supports multilingual press release distribution in English, Japanese, German, Korean, French, Russian, Indonesian, Malay, Vietnamese, Chinese, and more.